Compare PLCE & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLCE | ANIX |
|---|---|---|
| Founded | 1969 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.8M | 88.8M |
| IPO Year | 1997 | 2013 |
| Metric | PLCE | ANIX |
|---|---|---|
| Price | $3.54 | $2.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 632.5K | 100.0K |
| Earning Date | 04-10-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.48 | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $2.44 |
| 52 Week High | $9.56 | $5.46 |
| Indicator | PLCE | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 33.67 |
| Support Level | $2.90 | $2.44 |
| Resistance Level | $3.81 | $3.13 |
| Average True Range (ATR) | 0.42 | 0.14 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 17.41 | 2.56 |
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.